



ABOLOGIX signs a license agreement with Research Development Foundation for two monoclonal antibodies for oncology

- **ABOLOGIX gains exclusive, worldwide rights, to two R&D programs developed at the University of Geneva and funded by Institut Clayton de la Recherche**
- **The in-licensed programs focus on blocking two novel pharmacological targets: Junction Adhesion Molecule C (JAM-C) and Olfactomedin-like protein 3 (Olfml3)**
- **Potential new pharmacological approach for oncology patients**

Geneva, Switzerland, July 19, 2018.

Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.

During the past 10+ years Institut Clayton de la Recherche has funded research at the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva, mostly in the understanding of the biochemistry of cell adhesion molecules and extracellular matrix-related proteins in leukocyte transmigration and tumor angiogenesis.

As a result of this work monoclonal antibodies blocking JAM-C and Olfml3 have been obtained. They have shown initial promise in the treatment of a wide set of cancer indications.

“We are delighted to have the opportunity to continue the development of the programs that have been initiated at the University of Geneva. Antibodies blocking **JAM-C** and **Olfml3** have so far shown impressive potential in animal models of several cancer indications”, said Ignacio Faus, co-founder and Chairman of the Board of Abologix.

About Abologix

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule **JAM-C** and the extracellular matrix-related protein **Olfactomedin-like protein 3 (Olfml3)** for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève.

Contact Information

Ignacio Faus, Chairman of the Board

Abologix Sàrl

ignaciofaus@abologix.com